Back Refine search Reset
Please choose a search criteria from below
Filters Clear all
Specialties
Treatments

17 results found for Oncology in London

Sort by:
Showing 1 - 10 of 17 results
Oncology
Recommended by 2 specialists
17 years of experience
Medical Oncology

Dr Daniel Krell is a Consultant Oncologist, specialising in gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers and neuroendocrine tumours. He is experienced in using chemotherapy, targeted therapy and immunotherapy. Dr Krell also manages patients with cancer of unknown primary and is the clinical lead for this. He works as a member of the multidisciplinary team for gastro-oesophageal and hepatobiliary cancer at the Royal Free Trust. He is also the clinical lead for Neuroendocrine tumour oncology at The Royal Free Hospital.

He undertook oncology training at University College and the Royal Free Hospitals in London. In addition to his primary medical degree, he also gained a Bachelor’s degree in immunology and microbiology, in addition to a DPhil in Clinical Medicine at the University of Oxford’s Wellcome Trust Centre for Human Genetics and was funded by Cancer Research UK and HCA. His research involved the design of models to investigate the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer. This may help identify new therapeutic targets in this area. Dr Krell continues to be involved in clinical research and trials aimed at identifying new cancer therapies, focused on gastrointestinal, hepatobiliary and neuroendocrine tumours. He has published a number of peer-reviewed papers and presented at national and international conferences.

Diseases, Medical Tests and Treatments

  • Chemotherapy
  • Immunotherapy
  • Biological Therapy
  • Genetic Testing
  • Liver Cancer
  • Biliary Cancer
  • Bowel Cancer
  • Colorectal Cancer
  • Oesophageal Cancer
  • Pancreatic Cancer
Read more
Oncology
Recommended by 1 specialist
35 years of experience

Dr Katharine Pigott graduated from the University of London in 1995 having trained at The Middlesex Hospital. She specialised in Clinical Oncology training at The Westminster Hospital and Charing Cross Hospital. She also spent two years working as a research fellow at Mount Vernon Hospital and the Gray Laboratory running clinical trials in hyper fractionation and undertaking an MD in measuring late radiation damage. She took up a consultant post at The Royal Free in 1996 and worked there for twenty years specialising in the management and treatment of urological cancers and breast cancer.

During her time at The Royal Free, she was head of the Radiotherapy Department and Chair of The London Cancer Radiotherapy Expert Reference Group. Her clinical interests are research in breast and prostate cancer particularly in new radiotherapy technique and clinical trials. She was the radiotherapy lead for the TARGIT Academy at The Royal Free which taught intraoperative radiotherapy (IORT) to centres throughout the world and participated in the TARGIT trials.

She has published peer-review papers and co-edited books on the urological condition and intraoperative radiotherapy.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.


Diseases, Medical Tests and Treatments
  • Decision making for localised prostate cancer
  • Management of localised and metastatic prostate cancer
  • Management of breast cancer
  • External beam radiotherapy
  • Cyberknife
  • Rapid Arc/ Intensity-modulated radiotherapy
  • IORT intra-operative radiotherapy
  • Hormone treatment
  • Chemotherapy Radioisotope treatment
  • Decision making for localised prostate cancer
  • Management of localised and metastatic prostate cancer
  • Management of breast cancer
  • External beam radiotherapy
  • Cyberknife
  • Rapid Arc/ Intensity-modulated radiotherapy
  • IORT intra-operative radiotherapy
  • Hormone treatment
  • Chemotherapy Radioisotope treatment
Read more

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Read more
Oncology
17 years of experience

Dr Jonathan Krell is a Consultant Oncologist specialising in breast and gynaecological cancers, with particular interest in cancer genetics and hereditary malignancies, especially with respect of BRCA and other gene mutations. His clinical focus is on the systemic management of patients with gynaecological and breast cancers. 

Dr Krell qualified in medicine at Leeds University Medical School, where he also gained a first class honours degree in Pharmacology. He completed junior doctor positions at St James’ Hospital, Leeds and St Thomas’ Hospitals in London. He then undertook oncology training at Charing Cross and Hammersmith Hospitals.

His PhD work was funded by the Medical Research Council and this investigated the interplay between genetic mutations, DNA damage and the response to cancer therapeutics. Dr Krell is a leading member of the translational research team within the Cancer Research UK and Ovarian Cancer Action centres at Imperial College that aim to overcome resistance to current anti-cancer agents in ovarian and breast cancer.

Dr Krell has published more than 100 peer-reviewed papers in academic journals and he regularly presents on his research at national and international conferences.

 


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Radiotherapy
  • Genetic Testing
  • Breast Cancer
  • Ovarian Cancer
  • Gynaecological Cancers

 

Read more
Oncology
16 years of experience
Medical Oncology

Professor Peter Schmid is the Clinical Director of the St. Bartholomew Breast Cancer Centre, and Honorary Consultant Medical Oncologist and lead of the Cancer Immune Therapy group at Barts Hospital. He is also Professor of Cancer Medicine and Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute.

Professor Schmid studied medicine in Munich and Aberdeen. He was awarded scholarships by the German National Academic Foundation, the German Academic Exchange Service and the Hanns-Seidel-Foundation. Following this he completed specialist training in internal medicine, medical oncology and haematology in Berlin. Subsequently he undertook an MD in Clinical Chemistry at the Technical University Munich and a PhD in Medical Oncology at the Charité University in Berlin. In 2005, Professor Schmid moved to the UK and was appointed as Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. He was subsequently made Foundation Chair in Cancer Medicine at the University of Sussex.

He specialises in breast cancer, lung cancer and cancer immune therapy and is renowned internationally for this work in cancer immunotherapy. He was instrumental in the formation of the Cancer Immune Therapy group at Barts Hospital, which has become recognised globally as a leader in this field.

Professor Schmid has a particular research interest in triple negative breast cancer and endocrine resistance and has led more than 20 clinical studies and several translational research programmes in these areas. He also has an interest in personalised cancer medicine using novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. He currently leads an international group to establish blood-based circulating biomarkers.

He has authored or co-authored more than 150 publications and has published a book on the management of bone metastases. He is also regularly invited to speak at major international cancer conferences. Professor Schmid is a member of the breast cancer faculty of the European Society of Medical Oncology and has chaired several medical research committees. He was awarded the Breast Cancer Research Award 2012 by German Patient group Mammazone.

Professor Schmid has a strong interest in patient-doctor communication, for a number of years, he ran a programme training oncologists and oncology nurses in communication.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.


Diseases, Medical Tests and Treatments
  • Chemotherapy 
  • Immunotherapy 
  • Breast Cancer
  • Lung Cancer 
Read more
Oncology
17 years of experience
Clinical Oncology, Medical Oncology

Professor Tobias Arkenau is a renowned Consultant Medical Oncologist with HCA Healthcare at numerous locations including Sarah Cannon Research Institute, The Harley Street Clinic, The Princess Grace and The Wellington Hospital. Additionally, he holds an NHS post at University College London Hospital where he is a Professorial Research Associate.

He is a founding Medical Director of the Sarah Cannon Research Institute UK and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the HCA Healthcare UK Cancer Service Line. The talented physician has a wide range of experience in a variety of cancers, particularly gastrointestinal and skin cancers.

He was awarded his medical degree from Hanover Medical School in Germany in 2000. Following this, he completed his specialist training in oncology across numerous centres of excellence including the Royal Marsden Hospital. He was awarded a Fellowship by the Royal College of Physicians, and he is a key opinion leader in his field of Gastrointestinal Cancers, Drug Development and Immunotherapy for his reserach contributions to his field. During his career, he has published numerous peer reviewed articals and book chapters and contributes regulalry at international meetings such as ASCO, ESMO and AACR. He is leading the Sarah Cannon Institute UK as a Chief and Principal Investigator of numerous clinical trials of new anti-cancer drugs including immunotherapies and cellular therapies.

Diseases, Medical Tests and Treatments

  • Immunotherapy
  • Chemotherapy
  • Clinical Trials, Phase-1 studies
  • Drug Development, Experimental Therapies
  • TIL-Therapy
  • Biological Therapy
  • Video Consultation
  • Genetic Testing (Genomics Review Board)
  • Gastrointestinal Cancer
  • Skin Cancer
  • Upper Gastrointestinal Cancer
  • Lower Gastrointestinal Cancer
  • Melanoma
  • Bile Duct Cancer
  • Bowel Cancer
  • Colon Cancer
  • Gallbladder Cancer
  • Liver Cancer
  • Oesophagus Cancer
  • Pancreatic Cancer
  • Stomach Cancer
  • Small Bowel Cancer
Read more
Oncology
19 years of experience

Dr Timothy Robert Crook is a Consultant in Medical Oncology who works at The Princess Grace Hospital, The Harley Street Clinic, The Wellington Hospital and LOC.

He specialises in Bladder cancer, breast disease, chemotherapy, kidney cancer, oncology and skin cancer.


Diseases, Medical Tests and Treatments
  • Bladder cancer
  • Breast disease
  • Chemotherapy
  • Kidney cancer
  • Oncology
  • Skin cancer
  • Bladder cancer
  • Breast disease
  • Chemotherapy
  • Kidney cancer
  • Oncology
  • Skin cancer
Read more
Oncology
20 years of experience
Clinical Oncology

Dr Tom Richards is a consultant clinical oncologist specialising in the treatment of gastrointestinal (GI) and breast cancers. He is the clinical lead of the GI and breast cancer radiotherapy units at University College London NHS Hospital (UCLH) and honorary consultant in Clinical Oncology at The Whittington NHS Hospital. Prior to his appointment at UCLH, he was Clinical Oncology consultant in the GI and breast units at St Bartholomew's and The Royal London NHS Hospitals.

He is an experienced oncologist treating oesophagus, stomach, liver, pancreaticobiliary, colorectal and breast cancers. His specialist expertise is the delivery of radiotherapy, chemotherapy and biological targeted drugs for cancers at these sites. His particular interest is in technical radiotherapy treatments using cyberknife and intensity-modulated radiotherapy and motion management techniques using 4D-CT radiotherapy planning, deep inspiratory breath-hold and image-guided radiotherapy.

After graduation from Imperial College School of Medicine in London, his subsequent general internal medicine training was at King's College Hospital, London. He undertook specialist oncology training at St Bartholomew's and The Royal Marsden Hospitals in London. In 2015 he was awarded a PhD from the University of London for clinical and translation research performed at The Institute of Cancer Research, King's College London and The Royal Marsden Hospital. He studied the mechanisms by which therapeutic radiation affects normal tissues and strategies to detect and reduce late toxicity after curative treatment. He was awarded the Johnson and Johnson clinical research prize in 2012 for work contributing to his PhD.

He is a fellow of the Royal College of Radiologists and a member of The Royal College of Physicians, ESMO and ESTRO. He has spoken and chaired sessions at numerous national and international meetings. He is course tutor and examiner for the Institute of Cancer research MSc course and is the local principal investigator for several GI cancer clinical trials. Dr Richards is passionate to improve cancer outcomes, develop clinical research and deliver innovative multi-modality cancer treatments.


Diseases, Medical Tests and Treatments
  • Radiotherapy
  • Chemotherapy
  • SABR/Cyberknife
  • Intensity-modulated radiotherapy
  • SIRT (internal liver-directed radiotherapy)
  • Breast cancer
  • Colon cancer
  • Rectal cancer
  • Anal cancer
  • Oesophageal cancer
  • Liver cancer
  • Pancreatico-biliary cancer
Read more
Oncology
21 years of experience
Medical Oncology

I am a Medical Oncology Consultant for the Gastrointestinal Oncology Service at University College London Hospitals NHS Foundation Trust and Honorary Associate Professor at the UCL Cancer Insitute. I treat oesophageal, stomach, small bowel, colorectal and hepatobiliary cancers, as well as cancers of unknown primary. I am the UCLH Clinical Lead for the Cancer of Unknown Primary (CUP) Service and the Acute Oncology Service.


My research interests include immunotherapy for GI malignancies and Cancer of Unknown Primary, with focus on clinical trials and translational research of these cancers. I am Chief Investigator or Principal Investigator for a number of  GI or CUP immuno-oncology Phase 2 and 3 trials, including KEYNOTE 177, KEYNOTE 859, KEYNOTE 811, KEYNOTE 975,  VESTIGE, POLEM and CUPISCO.


I am Chair of the NCRI MUO-CUP Workstream as part of the Living With and Beyond Cancer CSG, and a member of the NCRI Colorectal Advanced and Adjuvant Disease Subgroup. I am the Principal Investigator of the UCL-UCLH GI + CUP Cancer Translational Research Biobank and a collaborator with the GI Oncology and CUP subgroups at the UCL Cancer Institute and Francis Crick Institute. I am a member of ASCO, ESMO and the Association of Cancer Physicans (UK).


I strongly believe in clinicians being educators and enjoy teaching oncology to UCL medical students, oncology and non-oncology junior trainees. I also give talks nationally and abroad at conferences and other hospitals to share best practice and future perspectives in the fields of GI oncology research, CUP, immunotherapy and novel trial designs.


To make an appointment or enquiry please contact my secretary Alanna Sarwar on asarwar@theloc.com or +44207 317 2659.


Diseases, Medical Tests and Treatments
  • Gastrointestinal Oncology - oesophageal, stomach, hepatobiliary and bowel cancers
  • Cancer of Unknown Primary
  • Acute Oncology
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Clinical Trials
  • Immunotherapy
  • Gastrointestinal Oncology Research 
  • Cancer of Unknown Primary Research 
  • Molecular Profiling with solid and liquid biopsies
  • Biomarker Driven Clinical Trial Design and Implementation
Read more
Dr Stephen Karp

Dr Stephen Karp

0.01 miles

Dr Stephen Karp

0.01 miles
Oncology
41 years of experience
Clinical Oncology

Dr Stephen Karp is a Consultant Clinical Oncologist at North Middlesex Hospital. His preclinical studies were at King’s College London where he also obtained an intercalated BSc in Pharmacology (1st Class Honours). He graduated in Medicine from Westminster Hospital Medical School in 1979 with a distinction in Surgery. His postgraduate training included cardiology at Hammersmith Hospital and neurology at the National Hospital Queen Square as well as general medicine at Whittington Hospital. He was a gastroenterology registrar at Northwick Park Hospital and trained in clinical oncology at the Middlesex Hospital and Mount Vernon Hospital.

Although Dr Karp was trained and initially practised in almost all areas of oncology, he is now specialized in treating cancers of the breast, GI tract (colorectal, oesophagogastric, pancreatic) and urological cancer (prostate and bladder cancer) with chemotherapy, hormone therapy, biological therapy and radiotherapy, including Cyberknife and SABR.


Diseases, Medical Tests and Treatments

  • Breast, gastrointestinal and prostate cancer (chemotherapy and radiotherapy)
  • IMRT IGRT
  • SABR
  • Cyberknife
  • Chemotherapy
  • Hormone therapy
  • Immunotherapy
  • Biological therapy
  • Breast, gastrointestinal and prostate cancer (chemotherapy and radiotherapy)
Read more